Maybe you can help me out green_street as I've read that presentation three times in the past few weeks and still can't translate it into today's announcement ...
I would have thought that people with mCRC (and their doctors and families) just want to know whether to be treated with SIR-Spheres and when. So does "failing OPFS but achieving PFS in the liver" mean being treated with SIR-Spheres (or treated with SIR-Spheres earlier) will extend life?
Any oncologists out there able to translate this result into plain English (ie I didn't use SIR-Spheres in the past, but now I will OR I didn't use them in the past, and still won't OR I used them in the past but will now use them earlier)?
Many thanks in advance ...
Clinical Trial Objectives, page-10
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $56.24M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 13.0¢ | $109.3K | 836.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 365703 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 812922 | 5 |
View Market Depth
| Last trade - 15.53pm 28/06/2024 (20 minute delay) ? |
| SRX (ASX) Chart |